-
-
-
-
-
-
-
Kitov Pharma (KTOV) Announces U.S. FDA Acceptance of Investigational NDA to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
-
-
-
-
-
-
-
Kitov Announces $10 million Registered Direct Offering
-
-
-
-
-
-
-
Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results
-
-
-
-
-
-
-
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
-
-
-
-
-
-
-
Kitov Pharma (KTOV) Presents Newly Released Data for NT-219 in Reversing Pancreatic Cancer Drug Resistance
-
-
-
-
-
-
-
Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements
-
-
-
-
-
-
-
Kitov Announces Key Milestone in FameWave Acquisition
-
1,166,569 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

